A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix and placebo, for the treatment of actinic keratosis with photodynamic therapy.

Trial Profile

A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix and placebo, for the treatment of actinic keratosis with photodynamic therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Aminolevulinic acid (Primary) ; Methyl aminolevulinate
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Biofrontera AG
  • Most Recent Events

    • 11 Feb 2016 Results from this trial will be presented at the 14th Annual South Beach Symposium, according to a Biofrontera media release.
    • 03 Jul 2012 Additional trial location (France) added as reported by European Clinical Trials Database record.
    • 06 Oct 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top